Scholarlink

Purpose <p>Lactate dehydrogenase (LDH) is an enzyme involved in the cellular energy metabolism of cancer cells. We conducted this study to evaluate serum LDH as a prognostic marker for predicting the outcomes of colorectal cancer (CRC) patients with negative carcinoembryonic antigen (CEA) and carbohydrate antigen 19 − 9 (CA19-9) levels.</p> Methods <p>The subjects of this retrospective study were 369 patients with stage II/III CRC and negative preoperative CEA and CA19-9 levels. Serum LDH levels were measured within 4 weeks before surgery and the association between serum LDH levels and survival outcomes was investigated.</p> Results <p>Fifty-five (15%) of the 369 patients had a high LDH of ≥ 212 U/L (high LDH group). Multivariate analysis identified that N stages 1‒3 (<i>P</i> = 0.019), serum LDH levels ≥ 212 U/L (<i>P</i> = 0.038), and a modified Glasgow Prognostic Score of 2 (<i>P</i> = 0.031) were independent predictors of disease-free survival (DFS). American Society of Anesthesiologists physical status ≥ 3 (<i>P</i> = 0.019), N stages 1‒3 (<i>P</i> = 0.009), and serum LDH levels ≥ 212 U/L (<i>P</i> &lt; 0.001) were also independent predictors of overall survival (OS).</p> Conclusion <p>The serum LDH level is a valuable prognostic marker for predicting the outcomes of CRC patients, even those with negative CEA and CA19-9 levels.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The prognostic value of serum lactate dehydrogenase levels in patients with carcinoembryonic antigen (CEA)- and carbohydrate antigen 19-9 (CA19-9)-negative colorectal cancer

  • 期刊论文

  • 发表日期：

    2025年12月12日

查看全文
  • Yasuhiro Takano,
  • Teppei Kamada,
  • Keisuke Goto,
  • Shu Tsukihara,
  • Yasunobu Kobayashi,
  • Yuta Imaizumi,
  • Shunjin Ryu,
  • Yasuhiro Takeda,
  • Masahisa Ohkuma,
  • Makoto Kosuge,
  • Ken Eto

摘要

Purpose

Lactate dehydrogenase (LDH) is an enzyme involved in the cellular energy metabolism of cancer cells. We conducted this study to evaluate serum LDH as a prognostic marker for predicting the outcomes of colorectal cancer (CRC) patients with negative carcinoembryonic antigen (CEA) and carbohydrate antigen 19 − 9 (CA19-9) levels.

Methods

The subjects of this retrospective study were 369 patients with stage II/III CRC and negative preoperative CEA and CA19-9 levels. Serum LDH levels were measured within 4 weeks before surgery and the association between serum LDH levels and survival outcomes was investigated.

Results

Fifty-five (15%) of the 369 patients had a high LDH of ≥ 212 U/L (high LDH group). Multivariate analysis identified that N stages 1‒3 (P = 0.019), serum LDH levels ≥ 212 U/L (P = 0.038), and a modified Glasgow Prognostic Score of 2 (P = 0.031) were independent predictors of disease-free survival (DFS). American Society of Anesthesiologists physical status ≥ 3 (P = 0.019), N stages 1‒3 (P = 0.009), and serum LDH levels ≥ 212 U/L (P < 0.001) were also independent predictors of overall survival (OS).

Conclusion

The serum LDH level is a valuable prognostic marker for predicting the outcomes of CRC patients, even those with negative CEA and CA19-9 levels.